Summary by Futu AI
HUTCHMED ANNOUNCED THAT IT WILL ANNOUNCE THE LATEST STUDY DATA ON ITS INDEPENDENTLY DEVELOPED COMPOUND AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING HELD IN CHICAGO, ILLINOIS, USA, FROM MAY 31 TO JUNE 4, 2024. These include the results of a Phase II registration study of furoquintin-conjugated cindylisone in patients with endometrial cancer, which supported the submission of a new drug listing application in China. IN ADDITION, KEY SUBGROUP UPDATE DATA FOR FRUTIGA PHASE III STUDY, FRESCO AND FRESCO-2 COLORECTAL CANCER PHASE III STUDY DATA, AND PRELIMINARY CLINICAL DATA FOR ERK1/2 INHIBITOR HMPL-295, ETC., WILL BE ANNOUNCED. These data will help to understand the research progress and clinical application potential of yellow medicine in the field of oncology therapy.